Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NOD1 is a key mediator of atrial myopathy in heart failure.

Theranostics·2026
Same author

Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system.

Frontiers in cardiovascular medicine·2026
Same author

Impact of Revascularization Completeness on Cardiovascular Outcomes in STEMI With Multivessel Disease.

Circulation. Cardiovascular interventions·2026
Same author

Intracardiac echo guided valvuloplasty of an early degenerated pulmonary valve-in-valve bioprosthesis.

Cardiovascular intervention and therapeutics·2026
Same author

Navigating Mechanical Support in Cardiogenic Shock With Arterial Hypoplasia: Lessons From Arterial Tortuosity Syndrome.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Bailout excimer laser coronary atherectomy for guidewire entrapment in a severely calcified left anterior descending artery complicated by dual perforation.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026

Related Experiment Video

Updated: May 19, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Everolimus-eluting coronary stents.

Alejandro Saez1, Raul Moreno

  • 1Division of Interventional Cardiology, University Hospital La Paz, Madrid, Spain.

Medical Devices (Auckland, N.Z.)
|August 24, 2012
PubMed
Summary

Everolimus-eluting stents effectively reduce restenosis and revascularization needs compared to bare metal stents. This review examines their evidence, including trials against other drug-eluting stents.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Bare metal stents reduced early complications but caused in-stent restenosis due to neointimal hyperplasia.
  • Drug-eluting stents (sirolimus-, paclitaxel-eluting) lower restenosis but carry risks of late stent thrombosis and require prolonged dual antiplatelet therapy.

Purpose of the Study:

  • To review current evidence for everolimus-eluting stents (EES).
  • To compare EES against bare metal stents (BMS) and other drug-eluting stents (DES).

Main Methods:

  • Systematic review of randomized controlled trials.
  • Analysis of head-to-head comparisons between EES and BMS.
  • Evaluation of EES versus other DES in clinical trials.
Keywords:
coronary stentseverolimusrestenosisreview

Related Experiment Videos

Last Updated: May 19, 2026

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
11:01

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

Main Results:

  • EES demonstrate significant reductions in restenosis and target lesion revascularization compared to BMS.
  • Head-to-head trials assess EES performance against other DES, evaluating efficacy and safety profiles.
  • Everolimus, a sirolimus analog, offers improved solubility, potentially impacting stent performance.

Conclusions:

  • Everolimus-eluting stents represent an advancement in coronary stent technology.
  • Evidence supports the use of EES for reducing restenosis and revascularization in interventional cardiology.
  • Ongoing comparisons with other DES will further define the optimal role of EES.